1)Aide N, Cappele O, Bottet P, et al:Efficiency of[(18)F]FDG PET in characterising renal cancer and detecting distant metastases:a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236-1245, 2003
2)Kang DE, White RL Jr, Zuger JH, et al:Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806-1809, 2004
3)Majhail NS, Urbain JL, Albani JM, et al:F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21:3995-4000, 2003
F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas:a preliminary report. J Cancer Res Clin Oncol 128:503-506, 2002
F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103:615-619, 2009
6)Lyrdal D, Boijsen M, Suurküla M, et al:Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519-524, 2009
F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma:preliminary study. Cancer Biother Radiopharm 24:137-144, 2009
F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer(EORTC)PET Study Group. Eur J Cancer 35:1773-1782, 1999
C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 36:422-427, 2009
10)Lawrentschuk N, Poon AM and Scott AM:Fluorine-18 fluorothymidine:a new positron emission radioisotope for renal tumors. Clin Nucl Med 31:788-789, 2006
11)Lawrentschuk N, Poon AM, Foo SS, et al:Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96:540-546, 2005